Study finds that lack of PRDX1 enhances immune activity and reduces tumor growth — Evidence Review
Published in Science, by researchers from University of Cambridge, Oregon Health & Science University
Researched by
— the AI search engine for science
Table of Contents
Researchers have found that certain immune cells require low levels of reactive oxygen species (ROS)—including free radicals—to attack cancer, and tumors may evade the immune system by releasing antioxidant proteins that quench these activating signals. Most related studies support this nuanced view, with evidence that antioxidant mechanisms can both protect and hinder immune responses against tumors, aligning with the findings from the University of Cambridge study.
- Several studies illustrate that tumor cells' antioxidant systems, such as xCT and PRDX1, are exploited to resist immune attack and promote tumor growth; disrupting these pathways can enhance antitumor immunity and sensitize tumors to immunotherapy 1 9.
- While traditional perspectives emphasize antioxidants' protective roles, emerging research demonstrates that manipulating tumor redox balance—either by increasing oxidative stress or targeting antioxidant proteins—can selectively impair cancer growth and boost immune cell effectiveness 3 9.
- The literature also underscores the complexity of ROS and antioxidants in cancer, with some studies noting that excessive antioxidant supplementation may inadvertently weaken immune responses, and that PRDX1 has diverse, context-dependent roles in both cancer cells and immune cells 2 6 7 8.
Study Overview and Key Findings
Understanding how cancer cells evade immune destruction is crucial for the development of more effective therapies. This study explores a previously underappreciated mechanism: tumors' ability to release antioxidant proteins, specifically Peroxiredoxin 1 (PRDX1), that dampen the local immune response by removing ROS signals necessary for T cell activation. The research integrates animal models, analysis of human tumor samples, and gene editing to build a comprehensive picture of how this antioxidant shield functions and how its removal may restore immune-mediated tumor control.
| Property | Value |
|---|---|
| Organization | University of Cambridge, Oregon Health & Science University |
| Journal Name | Science |
| Authors | Dr. Xan Wesolowski, Professor Rahul Roychoudhuri, Dr. Robert Eil |
| Population | Mice, human cancer cell lines, human tumors |
| Methods | Animal Study |
| Outcome | Tumor growth, immune cell activity, response to immunotherapy |
| Results | Without PRDX1, immune cells became more active, reducing tumor growth. |
Literature Review: Related Studies
To place the new findings in context, we searched the Consensus paper database, which includes over 200 million research papers, for studies on cancer, antioxidants, and immune system interactions. The following search queries were used:
- cancer antioxidants immune system interaction
- PRDX1 immune cell activation tumor growth
- tumor growth reduction immune response mechanisms
Literature Review Table
| Topic | Key Findings |
|---|---|
| How do tumor antioxidant mechanisms affect immune responses and tumor growth? | - Deleting or inhibiting tumor cell antioxidant systems (e.g., xCT, PRDX1) suppresses tumor growth and enhances antitumor immune responses, while maintaining T cell activity in vivo 1 9. - Tumor-released antioxidants can disrupt immune cell function and are associated with more aggressive tumor phenotypes 8 10. |
| What is the dual role of ROS and antioxidants in cancer and immunity? | - High levels of ROS can damage cells and promote cancer, but moderate ROS are important for immune cell activation; over-suppression of ROS with antioxidants can impair immune responses 2 3 4. - ROS-modulating therapies, including prooxidants and selective antioxidant targeting, may amplify the efficacy of immunotherapies 3 4. |
| What are the specific functions of PRDX1 in cancer and immune cells? | - PRDX1 supports survival and function of immune cells (e.g., NK cells) under oxidative stress, but in cancer cells, its presence is linked to increased growth, metastasis, and resistance to oxidative therapies 7 8 9 10. - Inhibition of PRDX1 in cancer cells impairs their growth and increases sensitivity to prooxidant agents 9. |
| How does the tumor microenvironment (TME) regulate immune evasion and therapy resistance? | - The TME modulates immune cell activity through metabolic, redox, and signaling factors; antioxidant proteins and TME metabolites contribute to immune evasion and limit immunotherapy efficacy 3 13 15. - Targeting TME factors, such as PRDX1 or xCT, can improve response to immunotherapies and reduce tumor growth 1 3 13. |
How do tumor antioxidant mechanisms affect immune responses and tumor growth?
Recent studies indicate that tumor cells often upregulate antioxidant mechanisms, such as xCT and PRDX1, to mitigate oxidative stress and evade immune destruction. The new study's finding that tumors release PRDX1 to suppress T cell activity aligns with prior research showing that disabling these antioxidant systems can slow tumor growth and boost immune responses.
- Disruption of tumor antioxidant proteins (xCT, PRDX1) impairs tumor growth and enhances antitumor immunity without harming T cell function in vivo 1 9.
- High PRDX1 expression is linked to increased tumor grade, metastasis, and poor prognosis in human cancers 10.
- Tumor-secreted antioxidants alter the local immune environment, making it less conducive to effective immune surveillance 8 10.
- Strategies that combine antioxidant inhibition with immunotherapy show greater efficacy than either approach alone 1 9.
What is the dual role of ROS and antioxidants in cancer and immunity?
The relationship between ROS and cancer is complex: while excessive ROS can promote DNA damage and carcinogenesis, moderate levels are necessary for immune cell signaling and tumor rejection. The new study's emphasis on the importance of ROS for T cell activation is supported by literature showing that both excessive ROS and excessive antioxidant activity can be detrimental, and that selective modulation of redox balance may optimize cancer therapy.
- High ROS levels can lead to oxidative stress, damaging cells and promoting diseases, but are also required for immune activation 2 3.
- Antioxidant supplementation has not reliably reduced cancer risk in clinical trials and may even impair immune surveillance in some contexts 2 3.
- ROS-modulating strategies, including prooxidants or inhibitors of tumor antioxidants, can enhance the effects of immunotherapies 3 4.
- Selenium and vitamin C have dose-dependent effects: at nutritional levels, they may support immunity, but at high doses, they can act as prooxidants and directly kill cancer cells or enhance immune responses 4 5.
What are the specific functions of PRDX1 in cancer and immune cells?
PRDX1 is a versatile antioxidant enzyme with context-dependent roles. In immune cells, PRDX1 supports survival under oxidative stress, but in cancer cells, it promotes growth, metastasis, and resistance to therapy. The new study's focus on PRDX1 as a tumor-derived immune evasion factor is consistent with findings that PRDX1 inhibition sensitizes cancer cells to oxidative damage and reduces tumor progression.
- PRDX1 overexpression in NK cells helps them withstand oxidative stress, suggesting a protective role in immune cells 7.
- In cancer cells, PRDX1 promotes proliferation, migration, and angiogenesis, and high levels correlate with poor prognosis 8 10.
- Knockdown or inhibition of PRDX1 selectively impairs cancer cell growth without significantly affecting non-cancerous cells 9.
- The dual roles of PRDX1 highlight the need for selective targeting to avoid impairing beneficial immune cell functions 7 9.
How does the tumor microenvironment (TME) regulate immune evasion and therapy resistance?
The TME is a complex milieu of metabolic, signaling, and immune-modulating factors that collectively determine tumor progression and response to therapy. Antioxidant proteins within the TME contribute to immune evasion by suppressing immune cell activation and promoting resistance to immunotherapies—a theme echoed in the new study.
- The TME accumulates metabolites and proteins that suppress immune cell activity, including antioxidants like PRDX1 3 13.
- Tumors use multiple mechanisms to evade immune attack, including induction of T cell exhaustion and metabolic reprogramming 13 15.
- Targeting TME components, such as antioxidant pathways, can improve the effectiveness of immunotherapies 1 3 13.
- Understanding the interplay between TME, immune cells, and tumor antioxidant systems is essential for designing more effective combination therapies 3 13.
Future Research Questions
While the new study advances understanding of how tumor-derived antioxidants suppress immune responses, several questions remain. Further research is needed to clarify the clinical implications, optimal therapeutic strategies, and broader applicability of these findings in diverse cancer types and patient populations.
| Research Question | Relevance |
|---|---|
| Does inhibiting PRDX1 in human cancers improve patient outcomes and response to immunotherapy? | Clinical studies are needed to determine if targeting PRDX1 can safely and effectively enhance immunotherapy in patients, as most current evidence is preclinical 1 9. |
| How do different levels of antioxidant supplementation affect immune surveillance against cancer? | Understanding the impact of dietary or supplemental antioxidants on immune function and cancer risk is crucial, given conflicting evidence from clinical and experimental studies 2 3. |
| What are the effects of PRDX1 modulation on non-tumor immune cells in the tumor microenvironment? | Since PRDX1 supports immune cell survival under oxidative stress, it's important to assess whether PRDX1 inhibition might impair beneficial immune responses or have unintended consequences 7. |
| Can combining PRDX1 inhibition with other redox-modulating agents further improve cancer immunotherapy? | Exploring combination therapies that target multiple antioxidant pathways or use prooxidants may yield synergistic effects and overcome resistance to current immunotherapies 3 4 9. |
| Which cancer types and patient subgroups are most likely to benefit from targeting tumor antioxidant mechanisms? | Identifying biomarkers and patient stratification strategies will help personalize therapies and maximize benefit from antioxidant pathway inhibition 8 10. |